LAVAL, QC – July 15, 2020 – As part of Sanofi Canada’s response to COVID-19, the Company is pleased to announce it is increasing access to financial assistance for its diabetes medications. Through the COVID-19 Response Program, Canadians with a valid prescription for a Sanofi diabetes medication can access an e-card through SanofiCares.ca, that when presented with a current prescription at their pharmacy, will provide up to 100% coverage for a single pack of the prescribed medications.[i] The card can be downloaded as often as needed.
“Sanofi Canada is proud to support Canadians living with diabetes, and we recognize the unprecedented challenges presented by the COVID-19 pandemic,” says Michael Mullette, General Manager, Sanofi Canada General Medicines. “By increasing access to financial assistance for our diabetes medications, we hope that we can provide some peace of mind during these uncertain times that the Sanofi medications they rely on will continue to be readily available and accessible.”
While the impact of COVID-19 continues to be understood, in general, people with diabetes are more likely to experience severe symptoms and complications when infected with a virus. There are indications that people with diabetes face a higher chance of experiencing serious complications from COVID-19, but the risk of getting very sick from COVID-19 is likely to be lower when the individual’s diabetes is well-managed.[ii]
More information on the COVID-19 Response Program is available at SanofiCares.ca.
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
Sanofi entities in Canada employ approximately 2,000 people. In 2018, we invested more than $127 million in R&D in Canada, creating jobs, business and opportunity throughout the country.
[i] Valid in Canada only. Coverage may vary by province.Please note, this Program may change or end at the manufacturer’s discretion.
[ii] American Diabetes Association. How COVID-19 Impacts People with Diabetes. https://www.diabetes.org/coronavirus-covid-19/how-coronavirus-impacts-people-with-diabetes
Accessed June 17, 2020.